Search Results - Favre‐Guilmard, Christine
- Showing 1 - 4 results of 4
-
1
Augmentation of VAMP-catalytic activity of botulinum neurotoxin serotype B does not result in increased potency in physiological systems by Elliott, Mark, Maignel, Jacquie, Liu, Sai Man, Favre-Guilmard, Christine, Mir, Imran, Farrow, Paul, Hornby, Fraser, Marlin, Sandra, Palan, Shilpa, Beard, Matthew, Krupp, Johannes
Published 2017Text -
2
A comparison of biological activity of commercially available purified native botulinum neurotoxin serotypes A1 to F1 in vitro, ex vivo, and in vivo by Donald, Sarah, Elliott, Mark, Gray, Bryony, Hornby, Fraser, Lewandowska, Agnieszka, Marlin, Sandra, Favre‐Guilmard, Christine, Périer, Cindy, Cornet, Sylvie, Kalinichev, Mikhail, Krupp, Johannes, Fonfria, Elena
Published 2018Text -
3
Recombinant botulinum neurotoxin serotype A1 in vivo characterization by Périer, Cindy, Martin, Vincent, Cornet, Sylvie, Favre‐Guilmard, Christine, Rocher, Marie‐Noelle, Bindler, Julien, Wagner, Stéphanie, Andriambeloson, Emile, Rudkin, Brian, Marty, Rudy, Vignaud, Alban, Beard, Matthew, Lezmi, Stephane, Kalinichev, Mikhail
Published 2021Text -
4
Engineered botulinum neurotoxin B with improved binding to human receptors has enhanced efficacy in preclinical models by Elliott, Mark, Favre-Guilmard, Christine, Liu, Sai Man, Maignel, Jacquie, Masuyer, Geoffrey, Beard, Matthew, Boone, Christopher, Carré, Denis, Kalinichev, Mikhail, Lezmi, Stephane, Mir, Imran, Nicoleau, Camille, Palan, Shilpa, Perier, Cindy, Raban, Elsa, Zhang, Sicai, Dong, Min, Stenmark, Pål, Krupp, Johannes
Published 2019Text